BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27995121)

  • 1. Effect of low-level laser therapy on bisphosphonate-treated osteoblasts.
    Shin SH; Kim KH; Choi NR; Kim IR; Park BS; Kim YD; Kim UK; Kim CH
    Maxillofac Plast Reconstr Surg; 2016 Dec; 38(1):48. PubMed ID: 27995121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined effect of recombinant human bone morphogenetic protein-2 and low level laser irradiation on bisphosphonate-treated osteoblasts.
    Jeong SY; Hong JU; Song JM; Kim IR; Park BS; Kim CH; Shin SH
    J Korean Assoc Oral Maxillofac Surg; 2018 Dec; 44(6):259-268. PubMed ID: 30637239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts.
    Kwon TK; Song JM; Kim IR; Park BS; Kim CH; Cheong IK; Shin SH
    J Korean Assoc Oral Maxillofac Surg; 2014 Dec; 40(6):291-6. PubMed ID: 25551094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of alendronate on expressions of osteoprotegerin and receptor activator of nuclear factor κB ligand in mouse osteoblasts].
    Dong W; Qi M; Deng J; Chen H; Feng X; Liao N
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Dec; 32(12):1695-8. PubMed ID: 23268391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of low-level laser therapy on oral keratinocytes exposed to bisphosphonate.
    Lee JY; Kim IR; Park BS; Kim YD; Chung IK; Song JM; Shin SH
    Lasers Med Sci; 2015 Feb; 30(2):635-43. PubMed ID: 23835780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates modulate the expression of OPG and M-CSF in hMSC-derived osteoblasts.
    Ohe JY; Kwon YD; Lee HW
    Clin Oral Investig; 2012 Aug; 16(4):1153-9. PubMed ID: 21938481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene.
    Cheung J; Mak YT; Papaioannou S; Evans BA; Fogelman I; Hampson G
    J Endocrinol; 2003 Jun; 177(3):423-33. PubMed ID: 12773123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanical stimulation effects on functional end effectors in osteoblastic MG-63 cells.
    Saunders MM; Taylor AF; Du C; Zhou Z; Pellegrini VD; Donahue HJ
    J Biomech; 2006; 39(8):1419-27. PubMed ID: 15953606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis.
    Hofbauer LC; Gori F; Riggs BL; Lacey DL; Dunstan CR; Spelsberg TC; Khosla S
    Endocrinology; 1999 Oct; 140(10):4382-9. PubMed ID: 10499489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice.
    Li X; Pilbeam CC; Pan L; Breyer RM; Raisz LG
    Bone; 2002 Apr; 30(4):567-73. PubMed ID: 11934647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2.
    Tsubaki M; Satou T; Itoh T; Imano M; Yanae M; Kato C; Takagoshi R; Komai M; Nishida S
    Mol Cell Endocrinol; 2012 Sep; 361(1-2):219-31. PubMed ID: 22579611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
    J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of intermedin on proliferation, apoptosis and the expression of OPG/RANKL/M-CSF in the MC3T3-E1 osteoblast cell line.
    Ren H; Ren H; Li X; Yu D; Mu S; Chen Z; Fu Q
    Mol Med Rep; 2015 Nov; 12(5):6711-7. PubMed ID: 26398911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
    Reyes-García R; Muñoz-Torres M; García DF; Mezquita-Raya P; García Salcedo JA; de Dios Luna J
    Menopause; 2010; 17(1):140-4. PubMed ID: 19574937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neuropeptide VIP regulates the expression of osteoclastogenic factors in osteoblasts.
    Persson E; Lerner UH
    J Cell Biochem; 2011 Dec; 112(12):3732-41. PubMed ID: 21815197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin.
    Shiotani A; Takami M; Itoh K; Shibasaki Y; Sasaki T
    Anat Rec; 2002 Oct; 268(2):137-46. PubMed ID: 12221720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-1 alpha stimulates the formation of osteoclast-like cells by increasing M-CSF and PGE2 production and decreasing OPG production by osteoblasts.
    Tanabe N; Maeno M; Suzuki N; Fujisaki K; Tanaka H; Ogiso B; Ito K
    Life Sci; 2005 Jun; 77(6):615-26. PubMed ID: 15921993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression.
    Kim YH; Kim GS; Jeong-Hwa B
    Exp Mol Med; 2002 May; 34(2):145-51. PubMed ID: 12085990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.